Everything should be made as simple as possible, but not simpler.
— Albert Einstein
Immuno-oncology therapy, the science of mobilizing the immune system to kill cancer, has been pursued for more than a century. Recently this powerful approach has taken the center stage in cancer therapies. Ipilimumab and nivolumab/pembrolizumab are among the earliest immune checkpoint inhibitors (targeting CTLA-4 and PD-1, respectively) and have transformed the therapeutic approach as new and promising tools for cancer management.
To effectively kill cancer cells by immune systems, a complete Cancer-Immunity Cycle (Chen & Mellman, 2013) including a series of stepwise events must be initiated and allowed to proceed and expand iteratively. Each step of the Cancer-Immunity Cycle requires the coordination of numerous stimulatory and inhibitory factors in nature.
There are two major constraints in advancing new cancer immunotherapies: differentiated biology in the lab that will faithfully translate into clinical benefits, and a working system to quickly prove the benefits in clinical settings.
At Elpiscience, we are focused on biological insights. We endeavor to find differentiated biology in the complex immune system that affects tumors. Elpiscience is fortunate to have science-driven talents searching for answers in the lab, world-renowned experts guiding our scientific strategies, and global collaborators sharing a common vision in the power of translational science to help patients.
Elpiscience: Meeting Immuno-oncology Challenges